New advances in multiple myeloma

Current Opinion in Hematology

Volumn 5, Issue 6, 1998, Pages 460-464

  Reece, Donna E ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BONE DESTRUCTION; CANCER SURVIVAL; CHROMOSOME ABERRATION; CYTOGENETICS; HERPES; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0031797746     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199811000-00018     Document Type: Review

References (48)

1. Hallek M, Bergsagel PL, Anderson KC: Multiple myeloma: Increasing evidence for a multistep transformation process. Blood 1998, 91:3-21. This review article discusses the critical steps thought to be involved in the malignant transformation of myeloma cells, including cytogenetic and molecular changes, role of the microenvironment and growth factors, and factors potentially leading to independent growth or inhibition of apoptosis.
2. Rettig MB, Ma HJ, Vescio RA, Fold M, Schiller G, Belson D, et al.: Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science 1997, 276:1851-1854. This is the first report describing the presence of Kaposi's sarcoma herpesvirus (or HHV-8) DNA sequences in dendritic cells cultured from the marrow of patients with myeloma, and, with a lower incidence, monoclonal gammopathy of undetermined significance. Infected cells were also found to contain RNA transcripts for viral interleukin-6.
3. Burger R, Neipel F, Fleckenstein B, Savino R, Ciliberto G, Kalden J, Gramatzki M: Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 1998, 91:1858-1863.
4. Santarelli R, Angeloni A, Farina A, Gonnella R, Gentile G, Martino P, et al.: Lack of serologic association between human herpesvirus-8 infection and multiple myeloma and monoclonal gammopathies of undetermined significance [letter]. J Natl Cancer Inst 1998, 90:781-782.
5. Masood R, Zheng T, Tulpule A, Arora N, Chatlynne L, Handy M, et al.: Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma [letter]. Science 1997, 278:1970-1971.
6. Brousset P, Meggetto F, Attal M, Delsol G: Kaposi's sarcoma-associated herpesvirus infection and myeloma [letter]. Science 1997, 278:1972.
7. Tisdale JF, Stewart AK, Dickstein B, Dube ID, Cappe D, Dunbar CE, Brown KE: Human herpesvirus 8 in patients with multiple myeloma. Blood 1997, 90(suppl 1):588a.
8. Berenson JR, Vescio RA, Said J: Multiple myeloma: The cells of origin-A two-way street. Leukemia 1998, 12:121-127.
9. Calasanz MJ, Cigudosa JC, Odera MD, Ferreira C, Ardanaz MT, Fraile A, et al.: Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations. Genes Chromosom Cancer 1997, 18:84-93.
10. Cigudosa JC, Rao PH, Calasanz MJ, Odero MD, Michaeli J, Jhanwar SC, Chaganti RSK: Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 1998, 91:3007-3010.
11. Perez-Simon JA, Garcia-Sanz R, Tabernero MD, Almeida J, Gonzalez M, Fernandez-Calvo J, et al.: Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood 1998, 91:3366-3371.
12. Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, Huh Y, Glassman A, Champlin R, Alexanian R: Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 1998, 101:189-194.
13. Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, et al.: A novel chromosomal translocation t(4;14) (p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 1997, 90:4062-4070.
14. Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S, et al.: Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997, 15:2659-2666. The absence of unfavorable cytogenetics, defined as abnormalities of 11q, partial or complete detection of 13, and the presence of any translocation, was the most important prognostic factor among 427 myeloma patients treated on a double autologous stem cell transplantation protocol. Duration of initial therapy and β2 microglobulin level were also important variables for outcome.
15. Fonseca R, Witzig TE, Gertz MA, Kyle RA, Hoyer JD, Jalal SM, Greipp PR: Multiple myeloma and the translocation t(11;14)(q13;q32): A report on 13 cases. Br J Haematol 1998, 101:296-301.
16. Calasanz MJ, Cigudosa JC, Odero MD, Garcia-Foncillas J, Marin J, Ardanaz MT, Rocha E, Gullon A: Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. Br J Haematol 1997, 98:418-425.
17. Feinman R, Sawyer J, Hardin J, Tricot G: Cytogenetics and molecular genetics in multiple myeloma. Hematol Oncol Clin North Am. 1997, 11:1-25.
18. Bensinger WI, Buckner CD, Gahrton G: Allogeneic stem cell transplantation for multiple myeloma. Hematol Oncol Clin North Am 1997, 11:147-157.
19. Lokhorst HM, Schattenberg A, Comelissen JJ, Thomas LLM, Verdonck LF: Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997, 90:4206-4211. This group's initial report has been increased to 13 patients treated with donor lymphocyte infusion for relapse after allogeneic transplantation; 4 achieved a complete response and 3 a partial response. Acute graft-versus-host disease was seen in the majority and 2 aplastic deaths were observed.
20. Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, et al.: Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998, 91:3671-3680. Among 40 patients with various hematologic disorders given donor CD4+ cells, five of six with myeloma responded. Graft-versus-host disease occurred in 32% with a mortality rate of 3%.
21. Munshi NC, Govindarajan R, Drake R, Ding LM, lyer R, Saylors R, et al.: Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 1997, 89:1334-1340.
22. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763. Nonmyeloablative therapy with fludarabine, busulfan, and antithymocyte globulin was given before allogeneic blood stem cell transplantation in 26 patients with hematologic disorders, including myeloma. Partial or complete chimerism was seen in all. The early disease-free survival rate was encouraging despite the development of severe graft-versus-host disease in seven patients.
23. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996, 335:91-97.
24. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al.: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997, 89:789-793.
25. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet G, Rossi JF, et al.: High dose therapy in multiple myeloma: An updated analysis of the IFM 90 protocol. Blood 1997, 90(Suppl 1):418a.
26. Jagannath S, Vesole D, Siegel D, Desikan KR, Munshi N, Fassas A, et al.: Final analysis of total therapy (TT) with tandem transplants (Tx) for 231 newly diagnosed patients (PTS) with multiple myeloma (MM). Blood 1997, 90(Suppl 1):418a-419a.
27. Attal M, Payen C, Facon T, Michaux JL, Guilhot F, Moconduit M, et al.: Single versus double transplant in myeloma: A randomized trial of the "Inter Groupe Francais du Myelome" (IFM). Blood 1997, 90(Suppl 1):418a.
28. Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M, et al.: Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995, 86:390-397.
29. Schiller G, Vescio R, Freytes C, Spitzer G, Lee M, Wu CH, et al.: Autologous CD34-selected blood progenitor cell transplants for patients with advanced myeloma. Bone Marrow Transplant 1998, 21:141-145.
30. Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, et al.: Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 1998, 91:4489-4495.
31. Bryne JL, Carter GI, Ellis I, Haynes AP, Russell NH: Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effect. Bone Marrow Transplant 1997, 20:517-520.
32. Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, et al.: Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem cell-rescue. J Clin Oncol 1997, 15:667-673.
33. Kwak LW, Sternas LA, Jagannath S, Siegel D, Munshi NC, Barlogie B: T-cell responses elicited by immunization of multiple myeloma patients with idiotypic M-protein plus GM-CSF in remission after autologous transplantation (PSCT). Blood 1997, 90(Suppl 1):579a.
34. Wen YJ, Ling M, Bailey-Wood R, Lim SH: Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 1998, 4:957-962. This case report describes vaccination with idiotype-pulsed dendritic cells, cultured from mobilized blood, in a refractory myeloma patient. Idiotype-specific T-cell and antibody responses were generated, associated with a minor paraprotein response. The immune response persisted for at least 2 months after subsequent autologous stem cell transplantation.
35. Bohlen H, Titzer S, Christensen O, Manzke O, Wolfe J, Thiele J, Diehl V, Tesch H: Dendritic cell based idiotypic vaccination in multiple myeloma. Blood 1997, 90(Suppl 1):579a.
36. Reichardt VL, Okada CY, Stockerl-Goldstein KE, Bogen B, Levy R: Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biol Blood Marrow Transplant 1997, 3:157-163.
37. Vescio R, Wu C, Rettig M, Stewart A, Ballester O, Noga S, et al.: The detection of KSHV is increased by mobilization chemotherapy and reduced in autografts by CD34-selection. Blood 1997, 90(suppl 1):565a.
38. Cull GM, Timms JM, Haynes AP, Russell NH, Irving WL, Ball JK, Thomson BJ: Dendritic cells cultured from mononuclear cells and CD34 cells in myeloma do not harbor human herpesvirus 8. Br J Haematol 1998, 100:793-796.
39. Tarte K, Olsen SJ, Lu ZY, Legouffe E, Rossi JF, Chang Y, Klein B: Clinicalgrade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirus. Blood 1998, 91:1852-1857. Dendritic cells were cultured from apheresis products in 11 myeloma patients; only 1 patient was weakly positive for human herpesvirus-8 by polymerase chain reaction. This level of detection was believed to be due to background prevalence of infection.
40. Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M, et al.: Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant 1997, 20:445-450.
41. Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR, et al.: Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 1998, 91:3518-3523. The incidence of new protein bands on immunofixation was 10% among 550 patients undergoing autologous stem cell transplantation. Evidence suggested that identification of such bands was associated with a favorable outcome and did not reflect adverse changes in myeloma activity.
42. Blade J, Samson D, Reece D, Apperley J, Bjokstrand B, Gharton G, et al.: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. BrJ Haematol, 102:1115-1123.
43. McCloskey EV, MacLennan ICM, Drayson MT, Chapman C, Dunn J, Kanis JA: A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998, 100:317-325.
44. Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M, et al.: Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial. Br J Haematol 1998, 101:280-286.
45. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998, 16:593-602. This randomized trial of intravenous pamidronate versus placebo evaluates the effect of 21 cycles of treatment. Pamidronate continued to reduce bony complications; a survival advantage was also seen in the subset of patients receiving salvage chemotherapy.
46. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A: In vitro cytoreductive effects on multiple myeloma cells induced by biphosphonates. Leukemia 1998, 12:220-229.
47. Shipman CM, Rogers MJ, Apperley JF, Russell RGG, Croucher PI: Biphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity. Br J Haematol 1997, 98:665-672.
48. Bloomfield DJ: Should biphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998, 16:1218-1225.